Pulmonx Corporation (Nasdaq: LUNG) reported a narrower loss than expected in the third quarter of 2023, posting a loss of $(0.39) per share, surpassing the consensus estimate loss of $(0.43) per share. The company's quarterly sales stood at $17.67 million, outpacing analysts' projections of $16.39 million in revenue.

Pulmonx adjusted its full-year 2023 revenue forecast to range from $67 million to $68 million, up from the previous guidance of $64 million to $66 million. This increase contrasts with the consensus estimate of $65.95 million in revenue for the period.

$LUNG was trading at $9.16 in after-hours, up $1.27 (+16.05%).

In another market development, shares of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) saw a surge of over 10% in after-hours trading. This rise came as the company announced the withdrawal of the underwritten public offering of its common stock. TransCode cited its decision as a reflection of the belief that the prevailing market conditions were not conducive to offering terms in the best interests of the company's stockholders.

$RNAZ was trading at $0.41 in the extended session, reflecting a significant rise of $0.06 (+15.62%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)